Health Reform WK-EDGE Firms bring in leading pharmaceutical, life sciences attorneys
Thursday, April 8, 2021

Firms bring in leading pharmaceutical, life sciences attorneys

By Rebecca Mayo, J.D.

Cooley added a life sciences corporate lawyer, DLA Piper added a pharmaceutical and medical device litigation team, and Latham & Watkins added a pharmaceutical regulatory lawyer.

Cooley. Cooley has added corporate lawyer Yiming Liu as a partner in the firm’s global capital markets practice. Liu is admitted to practice in New York and currently based in Shanghai, where his addition bolsters Cooley’s healthcare & life sciences platform and its capital markets, M&A, and partnering and licensing capabilities across the Asia Pacific region. He specializes in capital markets, M&A and technology transactions in the life sciences and high-tech industries, and has advised on numerous high-profile life sciences IPOs in recent years. Additionally, on behalf of clients in the US, Europe and China, Liu has successfully led the negotiation and documentation of a wide range of cross-border transactions, including M&A, private financings, joint ventures, and partnering and licensing arrangements.

DLA Piper. DLA Piper has added nationally recognized trial lawyer Lyn Pruitt, as well as Adria Conklin and Mary Catherine Way, as partners in the firm’s Litigation and Regulatory practice. Pruitt has first-chaired trials for a broad range of clients, including leading pharmaceutical and medical device companies, in major product liability and other complex cases over the past 20 years. Conklin and Way also bring years of experience and diverse experience advising and defending pharmaceutical and medical device clients in large product liability litigation matters. The addition of the team strengthens the firm’s trial bench and bolsters the firm’s ability to defend life sciences and other clients in mass tort, class action, and product liability cases.

Latham & Watkins. Latham & Watkins LLP has added leading pharmaceutical regulatory lawyer Christopher H. Schott as a partner in the Corporate Department and a member of the Healthcare & Life Sciences Practice. Schott is a leading practitioner in the area of drug price reporting and counsels pharmaceutical clients on a variety of healthcare, compliance, and regulatory matters, primarily related to the Medicaid, Medicare, and 340B drug pricing programs. He also advises clients in connection with pricing methodology audits and interactions with federal regulators as well as price reporting and compliance obligations which includes supporting the entire product lifecycle, from pre-launch considerations, to commercialization and contracting strategies, to decisions around authorized generics and line extensions.

Attorneys: Yiming Liu (Cooley LLP). Lyn Pruitt, Adria Conklin, Mary Catherine Way (DLA Piper). Christopher H. Schott (Latham & Watkins LLP).

IndustryNews: NewsLawFirm 340BNews DrugNews MedicalDeviceNews

Back to Top

Interested in submitting an article?

Submit your information to us today!

Learn More

Health Reform WK-EDGE: Breaking legal news at your fingertips

Sign up today for your free trial to this daily reporting service created by attorneys, for attorneys. Stay up to date on health reform legal matters with same-day coverage of breaking news, court decisions, legislation, and regulatory activity with easy access through email or mobile app.